Ischemic preconditioning-mediated restoration of membrane dystrophin during reperfusion correlates with protection against contraction-induced myocardial injury

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 1 56-1, 2004, Pages

  Kido, Masakuni ^a   Otani, Hajime ^a   Kyoi, Shiori ^a   Sumida, Tomohiko ^a   Fujiwara, Hiroyoshi ^a   Okada, Takayuki ^a   Imamura, Hiroji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

2,3 butanedione monoxime; Reperfusion injury

Indexed keywords

DIACETYL OXIME; DYSTROPHIN; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; HEART CONTRACTION; HEART INFARCTION PREVENTION; HEART MUSCLE; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART MUSCLE REPERFUSION; HEART PROTECTION; MALE; MUSCLE FIBER MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STABILITY; RAT; SARCOLEMMA;

ANIMALS; COLORING AGENTS; DIACETYL; DYSTROPHIN; EVANS BLUE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MEMBRANES; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 3042672852     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01140.2003     Document Type: Article

References (47)

1. Armstrong SC and Ganote CE. Effects of 2,3-butanedione monoxime (BDM) on contracture and injury of isolated rat myocytes following metabolic inhibition and ischemia. J Mol Cell Cardiol 23: 1001-1014, 1991.
2. Armstrong SC and Ganote CE. Flow cytometric analysis of isolated adult cardiomyocytes: vinculin and tubulin fluorescence during metabolic inhibition and ischemia. J Mol Cell Cardiol 24: 149-162, 1992.
3. Armstrong SC, Latham CA, Shivell CL, and Ganote CE. Ischemic loss of sarcolemmal dystrophin and spectrin: correlation with myocardial injury. J Mol Cell Cardiol 33: 1165-1179, 2001.
4. + exchange inhibitors for cardioprotective therapy: progress, problems and prospects. J Am Coll Cardiol 39: 747-753, 2002.
5. Avnur Z, Small JV, and Geiger B. Actin-independent association of vinculin with the cytoplasmic aspect of the plasma membrane in cell-contact areas. J Cell Biol 96: 1622-1630, 1983.
6. Bauza G, Le Moyec L, and Eugene M. pH regulation during ischaemia-reperfusion of isolated rat hearts, and metabolic effects of 2,3-butanedione monoxime. J Mol Cell Cardiol 27: 1703-1713, 1995.
7. Bhavanandan VP and Katlic AW. The interaction of wheat germ agglutinin with sialoglycoproteins. The role of sialic acid. J Biol Chem 254: 4000-4008, 1979.
8. Crestanello JA, Doliba NM, Babsky AM, Niibori K, Osbakken MD, and Whitman GJ. Mitochondrial function during ischemic preconditioning. Surgery 131: 172-178, 2002.
9. Ganote C and Armstrong S. Ischaemia and the myocyte cytoskeleton: review and speculation. Cardiovasc Res 27: 1387-1403, 1993.
10. Ganote CE and Armstrong SC. Dystrophin-associated protein complex and heart failure. Lancet 359: 905-906, 2002.
11. Ganote CE and Humphrey SM. Effects of anoxic or oxygenated reperfusion in globally ischemic, isovolumic, perfused rat hearts. Am J Pathol 120: 129-145, 1985.
12. Ganote CE and Vander Heide RS. Cytoskeletal lesions in anoxic myocardial injury. A conventional and high-voltage electron-microscopic and immunofluorescence study. Am J Pathol 129: 327-344, 1987.
13. Garcia-Dorado D, Theroux P, Duran JM, Solares J, Alonso J, Sanz E, Munoz R, Elizaga J, Botas J, Fernandez-Aviles F, Soriano J, and Esteban E. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation 85: 1160-1174, 1992.
14. ATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 285: H921-H930, 2003.
15. Habazettl H, Voigtlander J, Leiderer R, and Messmer K. Efficacy of myocardial initial reperfusion with 2,3 butanedione monoxime after cardioplegic arrest is time-dependent. Cardiovasc Res 37: 684-690, 1998.
16. Hoffman EP, Knudson CM, Campbell KP, and Kunkel LM. Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 330: 754-758, 1987.
17. Jennings RB, Reimer KA, and Steenbergen C. Myocardial ischemia revisited. The osmolar load, membrane damage, and reperfusion. J Mol Cell Cardiol 18: 769-780, 1986.
18. Kyoi S, Otani H, Sumida T, Okada T, Osako M, Imamura H, Kamihata H, Matsubara H, and Iwasaka T. Loss of intracellular dystrophin: a potential mechanism for myocardial reperfusion injury. Circulation 67: 725-727, 2003.
19. Lu K, Otani H, Yamamura T, Nakao Y, Hattori R, Ninomiya H, Osako M, and Imamura H. Protein kinase C isoform-dependent myocardial protection by ischemic preconditioning and potassium cardioplegia. J Thorac Cardiovasc Surg 121: 137-148, 2001.
20. Mackay K and Mochly-Rosen D. Localization, anchoring, and functions of protein kinase C isozymes in the heart. J Mol Cell Cardiol 33: 1301-1307, 2001.
21. Menke A and Jockusch H. Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature 349: 69-71, 1991.
22. Milner RE, Busaan JL, Holmes CF, Wang JH, and Michalak M. Phosphorylation of dystrophin. The carboxyl-terminal region of dystrophin is a substrate for in vitro phosphorylation by p34cdc2 protein kinase. J Biol Chem 268: 21901-21905, 1993.
23. 2+ overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res 89: 891-898, 2001.
24. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 94: 7-16, 2004.
25. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
26. Nayler WG and Elz JS. Reperfusion injury: laboratory artifact or clinical dilemma? Circulation 74: 215-221, 1986.
27. Ohlendieck K, Ervasti JM, Snook JB, and Campbell KP. Dystrophin- glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. J Cell Biol 112: 135-148, 1991.
28. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, and Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90: 3710-3714, 1993.
29. Rybakova IN, Patel JR, and Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 150: 1209-1214, 2000.
30. Schluter KD, Schwartz P, Siegmund B, and Piper HM. Prevention of the oxygen paradox in hypoxic-reoxygenated hearts. Am J Physiol Heart Circ Physiol 261: H416-H423, 1991.
31. Schulz R, Cohen MV, Behrends M, Downey JM, and Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res 52: 181-198, 2001.
32. Sebbag L, Verbinski SG, Reimer KA, and Jennings RB. Protection of ischemic myocardium in dogs using intracoronary 2,3-butanedione monoxime (BDM). J Mol Cell Cardiol 35: 165-176, 2003.
33. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, and Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578-1580, 1989.
34. Siegmund B, Klietz T, Schwartz P, and Piper HM. Temporary contractile blockade prevents hypercontracture in anoxic-reoxygenated cardiomyocytes. Am J Physiol Heart Circ Physiol 260: H426-H435, 1991.
35. Siegmund B, Koop A, Klietz T, Schwartz P, and Piper HM. Sarcolemmal integrity and metabolic competence of cardiomyocytes under anoxia-reoxygenation. Am J Physiol Heart Circ Physiol 258: H285-H291, 1990.
36. Steenbergen C, Hill ML, and Jennings RB. Cytoskeletal damage during myocardial ischemia: changes in vinculin immunofluorescence staining during total in vitro ischemia in canine heart. Circ Res 60: 478-486, 1987.
37. Straub V, Bittner RE, Leger JJ, and Voit T. Direct visualization of the dystrophin network on skeletal muscle fiber membrane. J Cell Biol 119: 1183-1191, 1992.
38. Straub V, Rafael JA, Chamberlain JS, and Campbell KP. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol 139: 375-385, 1997.
39. Tani M, Hasegawa H, Suganuma Y, Shinmura K, Kayashi Y, and Nakamura Y. Protection of ischemic myocardium by inhibition of contracture in isolated rat heart. Am J Physiol Heart Circ Physiol 271: H2515-H2519, 1996.
40. Vanden Hoek T, Becker LB, Shao ZH, Li CQ, and Schumacker PT. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ Res 86: 541-548, 2000.
41. Vander Heide RS, Angelo JP, Altschuld RA, and Ganote CE. Energy dependence of contraction band formation in perfused hearts and isolated adult myocytes. Am J Pathol 125: 55-68, 1986.
42. Vanoverschelde JL, Janier MF, and Bergmann SR. The relative importance of myocardial energy metabolism compared with ischemic contracture in the determination of ischemic injury in isolated perfused rabbit hearts. Circ Res 74: 817-828, 1994.
43. 2+ exchange current in guinea-pig cardiac ventricular myocytes. Br J Pharmacol 132: 1317-1325, 2001.
44. Weinbrenner C, Baines CP, Liu GS, Armstrong SC, Ganote CE, Walsh AH, Honkanen RE, Cohen MV, and Downey JM. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia. Circulation 98: 899-905, 1998.
45. Wiggins JR, Reiser J, Fitzpatrick DF, and Bergey JL. Inotropic actions of diacetyl monoxime in cat ventricular muscle. J Pharmacol Exp Ther 212: 217-224, 1980.
46. Yoshida H, Takahashi M, Koshimizu M, Tanonaka K, Oikawa R, Toyo-oka T, and Takeo S. Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction. Cardiovasc Res 59: 419-427, 2003.
47. Zimmermann N, Boknik P, Gams E, Gsell S, Jones LR, Maas R, Neumann J, and Scholz H. Mechanisms of the contractile effects of 2,3-butanedione-monoxime in the mammalian heart. Naunyn Schmiedebergs Arch Pharmacol 354: 431-436, 1996.